US 2003/0119897 A1 · Cd45 inhibitors

Abstract

Substituted naphthalenediones in accord with structural diagram (I): compositions thereof and methods for the use thereof, for the treatment of T cell mediated conditions such as autoimmune diseases and organ graft rejection. In compounds of the invention, wherein: Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3) alkyl and C(O)phenyl, and Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.

Claims6

Dependent claims

A method for treating immunologically-related diseases, autoimmune disorders and organ graft rejection comprising administering to a subject suffering therefrom an effective amount of a compound in accord with structural diagram I:

2
or tautomers thereof or pharmaceutically-acceptable salts thereof:
wherein:
Q1 at each occurrence is independently selected from hydrogen, hydroxy, halogen, C(O)O(C1-C3)alkyl and C(O)phenyl.
Q2 is selected from hydrogen, halogen, O—(C1-C3)alkyl, O—(C1-C3)alkenyl, phenyl, indolyl and naphthyl, where phenyl may be mono- or di-substituted with NO2 or halogen, and indolyl may be substituted with (C1-C3)alkyl or phenyl.

2 more elements

Dependencies are inferred from the claim text.

Cd45 inhibitors

Life of this patent

Cd45 inhibitors

Life of this patent

Abstract

Claims6